Penumbra (PEN) Stock Price, News & Analysis

Company Overview

Penumbra, Inc. (NYSE:PEN) is a medical device company that develops, manufactures and markets products designed to treat neurovascular, vascular and other medical conditions. Its technologies are used by physicians in minimally invasive procedures, including the removal of blood clots, treatment of aneurysms and management of vascular disorders.

The company’s product portfolio includes aspiration and mechanical thrombectomy systems for ischemic stroke and pulmonary embolism, embolization devices for aneurysms and other vascular conditions, and access and peripheral vascular products. Penumbra also offers equipment and accessories that support interventional procedures.

Founded in 2004 and headquartered in Alameda, California, Penumbra serves hospitals and healthcare providers in the United States and international markets. The company was founded by Adam Elsesser, who serves as its chairman, president and chief executive officer. Its products are distributed through direct sales organizations and other commercial channels worldwide.

Key Stats

• Today's Range: $317.30 to $319.33
• 50-Day Range: $316.32 to $327.14
• 52-Week Range: $221.26 to $362.41
• Volume: 816,973 shs
• Average Volume: 265,806 shs
• Market Capitalization: $12.56 billion
• P/E Ratio: 78.34
• Dividend Yield: N/A
• Price Target: $367.07
• Consensus Rating: Hold

Penumbra Stock Analysis - MarketRank™

Penumbra scored higher than 70% of companies evaluated by MarketBeat, and ranked 222nd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Hold

Consensus Rating

Penumbra has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on no strong buy ratings, 3 buy ratings, 14 hold ratings, and no sell ratings.

Upside Potential

Penumbra has a consensus price target of $367.07, representing about 15.1% upside from its current price of $318.84.

Amount of Analyst Coverage

Penumbra has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 23.39%

Earnings Growth

Earnings for Penumbra are expected to grow by 23.39% in the coming year, from $4.96 to $6.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Penumbra is 78.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.86.

Price to Earnings Ratio vs. Sector

The P/E ratio of Penumbra is 78.34, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.84.

Price to Earnings Growth Ratio

Penumbra has a PEG Ratio of 2.19. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Penumbra has a P/B Ratio of 8.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.53% of the float of Penumbra has been sold short.

Short Interest Ratio / Days to Cover

Penumbra has a short interest ratio ("days to cover") of 6.02.

Change versus previous month

Short interest in Penumbra has recently decreased by 4.80%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Penumbra does not currently pay a dividend.

Dividend Growth

Penumbra does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.92

News Sentiment

Penumbra has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Penumbra this week, compared to 5 articles on an average week.

Search Interest

2 people have searched for PEN on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Penumbra to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Penumbra insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.90% of the stock of Penumbra is held by insiders.

Percentage Held by Institutions

88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/17/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:PEN
• CIK: 1321732
• Web: www.penumbrainc.com
• Phone: (510) 748-3200
• Fax: 510-748-3232
• Employees: 4,700
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Penumbra: $367.07
• High Price Target: $388.00
• Low Price Target: $320.00
• Potential Upside/Downside: +15.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.18
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.07
• Trailing P/E Ratio: 78.34
• Forward P/E Ratio: 64.28
• P/E Growth: 2.19
• Net Income: $177.69 million
• Net Margins: 10.67%
• Pretax Margin: 13.55%
• Return on Equity: 10.50%
• Return on Assets: 8.17%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.75
• Quick Ratio: 3.86

Sales & Book Value

• Annual Sales: $1.40 billion
• Price / Sales: 8.95
• Cash Flow: $4.30 per share
• Price / Cash Flow: 74.07
• Book Value: $36.45 per share
• Price / Book: 8.75

Miscellaneous

• Outstanding Shares: 39,390,000
• Free Float: 38,247,000
• Market Cap: $12.56 billion
• Optionable: Optionable
• Beta: 0.70